A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, multicentre clinical study to evaluate the efficacy,
safety, tolerability, PK, and immunogenicity of SB17 compared to Stelara® in subjects with
moderate to severe plaque psoriasis.